Skip to main content

Eli Lilly results blow past estimates on strong Zepbound launch, higher Mounjaro prices

The quarterly results are the first to include sales of Eli Lilly's new weight loss drug Zepbound, which won FDA approval in early November.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.